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Abstract 
RalA, a ras p21 related 27 kDa GTP-binding protein, was expressed as a fusion protein in Escherichia coli and purified to 
homogeneity using an immunoaffinity column. The purified protein was capable of binding and hydrolyzing GTP. Addition of platelet 
cytosolic or detergent solubilized particulate proteins stimulated the intrinsic GTPase activity of raIA by at least six-fold with maximal 
effect observed at pH 6.5. Addition of platelet proteins denatured by boiling had no effect on ralA GTPase activity. Analysis of GTPase 
reaction products by thin layer chromatography demonstrated that in samples containing raIA, 78.5 + 6.3% of the radioactivity was 
recovered in the GTP form while samples containing ralA plus platelet cytosol or particulate proteins, only 7.5 + 0.2% and 9.0 + 1.4% 
of the radioactivity was in the GTP form respectively. The GTPase activating protein(s) in the cytosolic and particulate fraction was 
further characterized by measuring GAP activity in proteins eluted from gel slices after sodium dodecyl sulfate polyacrylamide gel 
electrophoresis. The ralA GTPase activating protein present in the cytosol and particulate fractions was recovered in a single gel slice of 
identical apparent molecular weight. The molecular mass of the ral specific GTPase activating protein was estimated to be 34 __. 2 kDa. 
This protein did not stimulate the intrinsic GTPase activity of ras p21, G25K/CDC42Hs or rab3A GTP-binding proteins. Results 
demonstrate that in human platelets, the activity/function of ral-related GTP-binding protein(s) is under the regulation of a specific 
GTPase activating protein of molecular mass of 34 __. 2 kDa that is distributed equally in the cytosol and particulate fraction. 
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1. Introduction 
The existence of  a large number of  GTP-binding pro- 
teins of  molecular mass between 20-27  kDa and with 
varying degree of  homology to the ras p21 proteins has 
been established in the eukaryotic cell [1-4]. As is the case 
for the heterotrimeric G-proteins, ras p21 and ras-related 
proteins exist in the GTP-bound form upon activation and 
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lino]ethanesulfonic acid; Pipes, piperazine-N,N'-bis[2-ethanesulfonic 
acid]; AMPPNP, 5'-adenylyl-imidodiphosphate; DTT, dithiothreitol; 
EDTA, ethylenediamine tetraacetic acid; PMSF, phenylmethanesulfonyl 
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are converted to the inactive GDP-bound form by the 
intrinsic GTPase activity associated with these proteins 
[5,6]. In comparison to the heterotrimeric G-proteins, ras 
p21 proteins have a lower intrinsic GTPase activity [5]. 
However, it has been shown that the GTPase activity of  
ras p21 can be stimulated by a cytoplasmic protein termed, 
GAP [7]. The effector region of ras p21 interacts with the 
GTPase activating protein suggesting an important role for 
GAP in ras p21 regulated signal transduction pathways 
[8]. The ras p21 specific GAP has been purified from 
bovine brain cytosol and shown to consist of  a single 
polypeptide chain of  molecular mass of  125 kDa [9]. The 
gene coding for ras -GAP has been cloned and sequenced 
from a bovine brain cDNA library [10] and the C-terminal 
region of  GAP is proposed to be necessary for its catalytic 
activity [11]. Insight into the structure of  r a s -G A P has also 
led to the identification of another protein termed, neurofi- 
bromin, as an activator of  the intrinsic GTPase activity of 
ras p21 [12,13]. 
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Studies on the regulation of GTPase activity of ras p21 
suggested that function of ras-related GTP-binding pro- 
teins may also be controlled in a similar fashion. This has 
led to the identification and characterization of GAPs for 
some ras-related GTP-binding proteins. Thus, specific 
GAPs have been purified for the r a p l A  [14,15], rho [16] 
and G25K/CDC42Hs [17] proteins. In case of the ras-re- 
lated GTP-binding protein coded for by the ral gene, a 
GAP activity has been detected in rat brain and mouse 
testis cytosol [18]. However, the identity of this protein has 
remained elusive. 
The purpose of the current study was to establish the 
identity of ral-GAP. The ral gene codes for a GTP-bind- 
ing protein of predicted molecular mass of 23.5 kDa that 
was originally cloned and sequenced from a simian B-cell 
cDNA library and shown to be ~ 50% homologous to the 
ras p21 protein [19]. Later, the ral gene was cloned and 
sequenced from a human placental cDNA library [20]. 
Now, two related ral genes, ralA and ralB, that are 
85% identical and differ essentially in their C-terminus 
region have been cloned and sequenced from a human 
pheochromocytoma [21], marine ray electric lobe [22] and 
rat liver [23] cDNA libraries. Previously, we have demon- 
strated the existence of a family of 23-27 kDa GTP-bind- 
ing proteins in platelet and other tissues that can be 
specifically labeled by incubation of [32 P]GTP with nitro- 
cellulose blots containing polypeptides separated using 
SDS-PAGE [24]. Using antibodies raised against recombi- 
nant raIA, we have also shown that part of the platelet 27 
kDa GTP-binding protein is coded for by the ral-related 
gene [25]. In addition, determination of the amino acid 
sequence of peptide fragments generated after digestion of 
a 28 kDa platelet GTP-binding protein has also confirmed 
the presence of ral gene product in human platelets [20]. 
However, the physiological function and biochemical regu- 
lation of ral protein in platelet has not been defined. The 
present report describes expression of ralA cDNA in E. 
coli, purification of recombinant protein to homogeneity 
and identification of a ral specific GTPase activating 
protein in the human platelet cytosol and particulate frac- 
tions. An abstract of this work has been published [26]. 
2. Materials and methods 
2.1. Materials 
The IBI pFLAG-1 Biosystem used for the expression 
and purification of raIA fusion protein from E. coli was 
obtained from InterSciences Inc. (Toronto, Ont., Canada). 
Restriction enzymes and other molecular biology reagents 
were from Pharmacia Canada Ltd. (Montreal, Que., 
Canada). DH5a strain of E. coli, ampicillin, IPTG and 
streptomycin sulfate were obtained from GIBCO-BRL 
(Oakville, Ont., Canada). Media for bacterial culture was 
from Difco Laboratories Ltd. (Detroit, MI, USA). Nitro- 
cellulose membrane (0.2 /zm pore), reagents and prestained 
protein markers for SDS-PAGE were from Bio-Rad Labo- 
ratories (Canada) (Mississauga, Ont., Canada). Schleicher 
and Schuell nitrocellulose membrane discs (0.45 /xm pore) 
and poly(ethylene)imine (PEI) cellulose thin layer chro- 
matography (TLC) sheets were obtained from Mandel 
Scientific Ltd. (Toronto, Ont., Canada). CHAPS and Tris 
were obtained from Boehringer Mannheim (Laval, Que., 
Canada). AMPPNP, adenosine-5'-triphosphate (ATP), 
guanosine-5'-triphosphate (GTP), Hepes, Mes, Pipes, BSA, 
DTT, EDTA, PMSF and low molecular weight protein 
markers for SDS-PAGE were obtained from Sigma Chemi- 
cal Co. (St. Louis, MO, USA). [y-32p]GTP (6000 
Ci/mmol)  was from Dupont Canada (Mississauga, Ont., 
Canada). [ a- 32 P]GTP (3000 Ci/mmol)  was obtained from 
ICN Radiochemicals (Irvine, CA, USA). Liquid scintilla- 
tion cocktail was from Beckman Instruments (Canada) 
(Mississauga, Ont., Canada). All other reagents used were 
of analytical grade. 
2.2. RalA expression and purification 
Ra lA  was expressed as a fusion protein linked to the 
C-terminal end of flag peptide of the expression vector, 
pFLAG-1. For in frame cloning, an ~ 900 base pair 
HindlII cDNA fragment containing the complete coding 
sequence for ralA [20] was inserted into the unique HindlII 
multiple cloning site of the pFLAG-1 vector and used to 
transform competent DH5c~ E. coli cells. Bacteria were 
spread on Luria-Bertaini (LB)-agar plates containing 50 
/xg/ml ampicillin and allowed to grow overnight at 37°C. 
Several colonies were randomly picked and for preparing 
plasmid DNA, 2 ml bacterial cultures were grown overnight 
in LB medium containing 50 /xg/ml ampicillin. Since 
ralA gene has a single EcoRI site approximately 50 base 
pairs downstream of the initiation codon [19] and the 
pFLAG-1 vector also contains a unique EcoRI site in the 
multiple cloning site, HindlII or EcoRI digestion was used 
to establish the presence and orientation respectively of the 
ralA insert in plasmid DNA preparations. Four bacterial 
colonies were positive for the insert with three containing 
the ralA cDNA in the correct orientation. To detect ex- 
pression of the raIA fusion protein, colonies containing 
the insert were cultured overnight in LB medium contain- 
ing 50 /~g/ml ampicillin followed by a further 7 h in the 
absence or presence of IPTG. The bacterial proteins were 
separated by SDS-PAGE, the gel stained with Coomassie 
Blue or electroblotted to nitrocellulose and blot incubated 
with [ c~-32 P]GTP as described below. 
To purify the ralA fusion protein, 2 1 culture of a 
positive bacterial colony was grown overnight at 37°C in 
LB medium containing 50 /zg/ml ampicillin followed by 
a further 7 h in the presence of 1.5 mM IPTG in the same 
culture medium. The bacteria were harvested by centrif- 
ugation and pellet resuspended in 50 ml of phosphate- 
buffered saline (0.01 M NaH2PO 4, pH 8.4, 0.15 M NaC1 
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and 1 mM PMSF) which also contained 0.25 mg/ml  
lysozyme. The bacterial suspension was lysed by freeze- 
thaw (3 times in liquid N 2) and by incubation at 37°C for 
30 min. The lysate was centrifuged at 25 000 X g for 45 
min at 4°C. To reduce vJiscosity and precipitate DNA, 
enough streptomycin sulfate was added to the supernatant 
to achieve a final concentration of 2.5% (w/v) .  After 
stirring at 4°C for 30 min, the suspension was centrifuged 
at 10000 X g for 10 min at 4°C. For purification of the 
ralA fusion protein, supernatant was passed through an 
affinity column that had covalently bound antibody against 
the flag peptide (provided with the pFLAG-1 vector). After 
washing the column three times with phosphate-buffered 
saline (0.01 M NaH2PO 4, I:,H 7.4, 0.15 M NaCI and 1 mM 
PMSF), raIA fusion protein was eluted from the im- 
munoaffinity column using 0.1 M glycine (pH 3.0). The 
fractions containing ralA were immediately neutralized by 
the addition of 1 M Tris and stored at -70°C until further 
use. 
2.3. Preparation of platelet particulate and cytosolic frac- 
tion 
the addition of 1 N NaOH, samples were heated for 3 min 
at 100°C and analyzed by SDS-PAGE with 13% (w/v )  
acrylamide in the separating gel [24,27]. 
2.6. Detection of proteins capable of binding [oz-32p]GTP 
on nitrocellulose blots 
The procedure has been described in detail elsewhere 
[24] and was used with minor modification. Briefly, poly- 
peptides separated using SDS-PAGE were electroblotted to 
nitrocellulose using a transfer buffer containing 0.05% 
SDS [24,28] and the blot incubated for 30 min at 20°C in a 
buffer containing 50 mM Tris-HCl, pH 7.5, 0.3% (w/v )  
Tween 20 (buffer B) and 5% milk powder. At the end of 
this period, the blot was washed in buffer B (three times 
for 5 min each) and incubated for a further 30 min at 20°C 
in buffer B that also contained 1.0 /zCi/ml [ a  -32 P]GTP 
(final concn. 1 nM), 2 /zM ATP and 4 / zM MgC12. After 
washing three times in the same buffer without GTP, blots 
were air-dried and bound 32p detected by autoradiography 
(12-24 h at -70°C, using a Cronex intensifying screen, 
Picker International, Brampton, Ont., Canada). 
Human platelets were obtained from the local Red 
Cross. To remove contaminating red blood cells, the 
platelet concentrate was ce.ntrifuged at 160 X g for 30 s 
and the pellet discarded. The supernatant was further cen- 
trifuged at 2000 X g for 15 min and the platelet pellet 
washed three times in a medium containing 13 mM 
trisodium citrate, 5 mM dextrose and 135 mM NaCI (pH 
6.5). The final platelet pellet was resuspended in a buffer 
containing 10 mM Tris-HC1, pH 7.5, 5 mM EDTA and 1 
mM PMSF (buffer A). The platelets were lysed by freeze- 
thaw (three times in liquid N 2) and the cytosolic and 
particulate fractions prepared by centrifugation at 100 000 
X g for 1 h at 4°C. The particulate pellet was resuspended 
once more in buffer A and centrifuged at 100000 × g for 
1 h at 4°C. The cytosotic and particulate fractions were 
stored at -70°C until further use. 
2.4. Solubilization of platelet particulate proteins 
The platelet particulate fraction obtained in Section 2.3 
was stirred for 1 h at 4°C in buffer A which also contained 
1% CHAPS. The suspension was centrifuged at 100000 X 
g for 1 h at 4°C and the supernatant containing solubilized 
proteins was stored at -70°C until further use. 
2.5. Sodium dodecyl sulfate polyacrylamide gel elec- 
trophoresis 
Samples containing protein were precipitated by the 
addition of trichloroacetic acid to a final concentration of 
10% (w/v) .  Precipitated proteins were collected by cen- 
trifugation and solubilized in 50 /zl of electrophoresis 
sample buffer [27]. After neutralization of residual acid by 
2.7. GTPase assay 
The GTPase activity was assayed by measuring loss of 
32p from ralA that had been preloaded with [y-32p]GTP. 
The procedure is a modification of the method described in 
[7]. Briefly, in the first step of the assay, ralA fusion 
protein ( ~  2 /zg) was incubated in a total volume of 100 
/xl for 15 min at room temperature in buffer containing 20 
mM Tris-HC1, pH 7.5, 1 mM DTT, 0.1 mM AMPPNP, 2 
mM EDTA, 40 mg/ml  BSA and 0.5 mM [T-32p]GTP 
(100 Ci/mmol). In the second step, an aliquot (15 ng) of 
[T-32p]GTP loaded ralA was added to a mixture (total 
vol = 50 /zl) containing 20 mM Tris-HC1, pH 7.5, 100 
mM NaC1 and 10 mM MgCI 2 and incubated for 15 min at 
room temperature. The reaction was terminated by the 
addition of 1 ml of ice-cold stopping buffer (20 mM 
Tris-HC1, pH 7.5, 100 mM NaC1 and 5 mM MgC12) and 
contents quickly filtered through nitrocellulose discs using 
the Millipore filtration apparatus. After washing five times 
(2 m l /  wash) with stopping buffer, 10 ml of scintillation 
fluid was added and radioactivity associated with filters 
quantitated using a Beckman 5801 liquid scintillation 
counter. 
To analyze products of the GTPase assay by thin layer 
chromatography, after filtration and washing, nitrocellu- 
lose filters were suspended in 500 /xl of 0.1 N HC1 to 
extract the guanine nucleotides. The sample was adjusted 
to pH 7.2 by the addition of 130 ~1 of 0.5 M Tris [29]. 
After making the extract 1 mM in GTP and GDP, an 
aliquot was spotted on poly(ethylene)imine cellulose sheets 
and chromatographed using 1 M KH2PO 4 [29]. The GTP 
and GDP spots were visualized using autoradiography 
(12-24 h at -70°C,  using a Cronex intensifying screen, 
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Picker International, Brampton, Ont., Canada). To deter- 
mine radioactivity associated with GTP and GDP, the 
appropriate spot was cut out and quantitated using liquid 
scintillation counting as described above. 
3. Results  
3.1. Expression of  ralA in E. coli and purification oj 
recombinant protein 
2.8. Detection o f  GAP activity 
To establish presence of raIA specific GAP in human 
platelets, the GTPase activity was measured as described 
above except that in the second step of the assay, platelet 
cytosolic or detergent solubilized particulate proteins were 
added to the reaction mixture. 
To determine optimal pH for GAP activity, platelets 
were lysed by freeze-thaw in buffer containing 10 mM 
Mes (pH 5.5) or 10 mM Mes (pH 6.0) or 10 mM Pipes 
(pH 6.5) or 10 mM Hepes (pH 7.0) or 10 mM Tris-HC1 
(pH 8.0) plus 5 mM EDTA and 1.0 mM PMSF. The 
cytosolic fraction was prepared as described above and 
used for measuring GAP activity. The GTPase assay was 
carded out as in Section 2.7 except that buffer used in the 
GAP assay was identical to that used for lysing the platelets. 
The cDNA containing the complete coding sequence for 
human ralA was subcloned into the pFLAG-1 vector and 
the fusion protein expressed in DH5c~ strain of E. coli. 
Four clones were positive for the ralA cDNA with three 
containing the insert in the correct orientation. Upon addi- 
tion of IPTG to the culture medium, bacterial colonies 
containing the ralA cDNA in the correct orientation ex- 
pressed a fusion protein of predicted molecular mass of 30 
kDa. The ralA fusion protein expressed in E. coli bound 
GTP when nitrocellulose blots containing polypeptides 
separated by SDS-PAGE were incubated with [ c~- 32 P]GTP. 
The ralA fusion protein was purified to homogeneity in 
a single step using an immunoaffinity column that con- 
tained covalently bound antibody against the flag peptide 
(Fig. 1A, lanes 2 and 3). The average yield of the fusion 
protein was ~ 0.5 mg from an overnight 2 1 bacterial 
2.9. Detection o f  GAP activity after SDS-PAGE 
To obtain an estimate of the molecular mass of platelet 
ral-GAP, 1 vol. of 5 × Laemmli's sample buffer [27] was 
added to 4 vol. of solution containing cytosolic or deter- 
gent solubilized particulate proteins. The sample was heated 
at 56°C for 3 min and the cytosolic and particulate proteins 
separated using SDS-PAGE in alternate lanes in duplicate 
alongwith molecular weight markers. One part of the gel 
containing platelet proteins and molecular weight markers 
was stained using Coomassie Blue and the second equiva- 
lent part was equilibrated by shaking for 15 min at room 
temperature in a buffer containing 10 mM Tris-HCl, pH 
7.5, and 1 mM DTT. This gel portion was cut into slices 
from the top to the dye front followed by a cut in the 
middle of each slice to obtain the cytosolic and particulate 
protein sample. Individual gel slices were incubated in 150 
/zl of equilibration buffer at 37°C for 1 h with mixing 
every 10 min. At the end of this incubation period, an 
aliquot of the supernatant from each gel piece was assayed 
for the presence of ral-GAP activity using the GTPase 
assay described above. 
2.10. Protein assay 
Samples containing proteins were precipitated by the 
addition of trichloroacetic acid to a final concentration of 
10% (w/v) .  After solubilizing the pellet, protein was 
determined by the method of Lowry et al. [30] using a 
protein standard solution that contained 5% (w/v )  human 
albumin and 3% ( w / v )  human globulin. 
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Fig. 1. Purification of E. coli expressed ralA, A 2 1 bacterial culture 
expressing the ralA protein was grown overnight. 7 h after the addition 
of IPTG, bacterial cytosolie fraction was prepared and the fusion protein 
purified as described in Section 2. (A) represents polypeptides separated 
by SDS-PAGE and visualized using Coomassie Blue. Molecular weight 
markers (lane 1), total bacterial proteins after lysis of bacteria by the 
addition of Laemmli's sample buffer (lane 2, 50 /zg) and the purified 
ralA fusion protein (lane 3, 50/zg). (B) shows an autoradiograph of total 
bacterial proteins (lane 2) and purified ralA (lane 3) that were separated 
using SDS-PAGE, electroblotted to nitrocellulose and incubated with 
[ or- 32 P]GTP. 
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Fig. 2. Detection of raI-GAP activity in human platelets. Cytosolic and 
detergent solubilized particulate protein fractions were prepared as de- 
scribed in Section 2. To measure: GAP activity, 50 /zg of cytosolic or 
detergent solubilized particulate proteins were added to mixture contain- 
ing 15 ng ralA loaded with [y--~'2p]GTP. After 15 min incubation, the 
mixture was passed through a nitrocellulose disc and radioactivity associ- 
ated with the filter was quantitated as described in Section 2. Data 
represent the average + S.D. of at least three independent experiments. 
culture. However, the purified ralA fusion protein was 
cleaved at the C-terminus ( ~  20 amino acids truncated) as 
it demonstrated faster mobility on SDS-PAGE analysis 
compared to the protein present in bacteria that were 
denatured immediately by the addition of Laemmli's sam- 
ple buffer (Fig. 1A, lanes 2 and 3). Further support for this 
comes from studies on binding of [ a -32 P]GTP on nitro- 
cellulose blots containing polypeptides separated by SDS- 
PAGE. As shown in Fig. 1B, the ralA fusion protein 
present in bacteria that were dentaured immediately by the 
addition of Laemmli's sample buffer (lane 2) had a mobil- 
ity on SDS-PAGE slower than that of the purified fusion 
protein (lane 3). In addition, purified ralA fusion protein 
was retained when passed :for the second time through the 
pFLAG immunoaffinity column, confirming that the pro- 
tein was cleaved at the C-terminus (results not shown). 
Variations in bacterial growth conditions, inclusion of a 
wide variety of proteolytic inhibitors during lysis of bacte- 
ria and purification steps did not protect the fusion protein 
from partial degradation. 
3.2. Detection of  GTPase activating protein 
0.4 
o . a  
~ 0.2  
m 
o 
"~ 0.1 
b~ 
0.0  
Control  
Boiled Cytosol  
Boiled M e m b r a n e  
Fig. 3. Effect of protein denaturation on raI-GAP activity. Human 
platelet cytosolic and particulate proteins were heated at 100°C for 5 min. 
The denatured proteins were pelleted by centrifugation and supernatant 
added to GTPase assay. The GAP activity was measured as described in 
Section 2. 
cytosolic or particulate proteins were first denatured by 
boiling and the supernatant added to the assay, no increase 
in the GTPase activity of ralA was observed (Fig. 3) 
suggesting that a protein(s) was responsible for GAP activ- 
ity. When ralA preloaded with [ a -32 P]GTP was used to 
measure GTPase activity, addition of cytosolic or particu- 
late proteins to the reaction mixture did not cause a 
decrease in the amount of radioactivity associated with 
ralA at the conclusion of the assay (results not shown). 
These results confirm that the addition of platelet proteins 
to the GTPase assay did not promote an exchange or 
removal of GTP bound to ralA. 
To obtain additional support for the observation that 
protein(s) present in the cytosolic and particulate fraction 
increased the intrinsic GTPase activity of ralA, fusion 
protein was preloaded with [ a -32 P]GTP and products of 
the GTPase assay were analyzed by thin layer chromatog- 
1 2 3 
GDP 
GTP 
The ralA fusion protein purified from E. coli was 
preloaded with [y-32p]GTP to establish the presence in 
human platelets of a protein(s) that could stimulate the 
intrinsic GTPase activity of ralA. Results presented in Fig. 
2 demonstrate that addition of platelet cytosolic or deter- 
gent solubilized particulate proteins to the assay stimulated 
the GTPase activity of ralA resulting in at least a six-fold 
increase in the rate of GTP hydrolysis. The cytosolic 
fraction contained higher ral-GAP activity (Fig. 2). When 
Fig. 4. Analysis of GTPase assay products by thin layer chromatography. 
ralA protein was preloaded with [a-32p]GTP and used in the GAP assay 
as described in Section 2. After filtration, guanine nucleotides trapped on 
nitrocellulose filters were eluted using 0.1 N HCI. The pH of the eluant 
was adjusted to 7.2 by the addition of 0.5 M Tris and after the addition of 
1 mM GTP and 1 mM GDP, an aliquot was spotted on poly(ethylene)im- 
ine cellulose sheets and chromatographed using 1 M KH2PO 4. The GTP 
and GDP spots were visualized using autoradiography. The figure above 
represents, ralA alone (lane 1), ralA plus 50 /zg  of cytosolic (lane 2) and 
ralA plus 50 /zg of detergent solubilized particulate (lane 3) proteins. 
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Fig. 5. Determination of optimal pH for ral-GAP activity. Human 
platelets were lysed in buffers of various pH values. The cytosolic 
fraction was prepared as described in Section 2. 50 /xg of cytosolic 
proteins were added to reaction mixture containing ralA preloaded with 
[y-32p]GTP and GAP activity measured as described in Section 2. GAP 
activity shown above represents the percentage decrease in the amount of 
radioactivity associated with ralA in the presence of GAP versus that 
associated with ralA in the absence of platelet proteins. 
raphy. As shown in Fig. 2 and in Fig. 4 (lane 1), the ralA 
fusion protein had a relatively low intrinsic GTPase activ- 
ity (0.0448 _ 0.0056 pmol GTP hydrolyzed/min per pmol 
protein). However, addition of cytosolic (Fig. 4, lane 2) or 
detergent solubilized particulate (Fig. 4, lane 3) proteins to 
the assay stimulated the GTPase activity resulting in an 
increase in the amount of [ce-32p]GDP associated with 
ralA. Quantitation of the radioactivity associated with 
ralA at the end of the GTPase assay demonstrated that, in 
case of the samples containing ralA protein (Fig. 4, lane 
1), 78.5 + 6.3% (n = 3) of the radioactivity associated 
with the protein was in the GTP form. However, in 
samples containing raIA plus cytosolic (Fig. 4, lane 2) or 
detergent solubilized particulate (Fig. 4, lane 3) proteins, 
only 7.5 + 0.2% (n = 3) and 9.0 + 1.4% (n = 3) of the 
radioactivity was recovered in the GTP form respectively. 
This alongwith data presented in Fig. 2 demonstrate that 
the intrinsic GTPase activity of ralA was stimulated at 
least six-fold due to the presence of a GTPase activating 
protein(s) in the platelet cytosolic and particulate fraction. 
3.3. Effect of pH on cytosolic GAP activity 
To measure the effect of pH on stimulation of ralA 
GTPase activity by GAP, platelets were lysed in buffers of 
different pH values and the cytosolic fraction prepared as 
described in Section 2. As shown in Fig. 5, maximal 
stimulation of ralA GTPase activity by GAP occurred at 
pH 6.5 and decreased slightly between pH 7.0 and 8.0. 
However, the raIA-GAP activity was reduced consider- 
ably at pH below 6.5 (Fig. 5). 
3.4. Characterization of platelet cytosolic and particulate 
GAP(s) 
Initial studies to determine the size of ral-GAP by 
molecular exclusion chromatography (AcA34) suggested 
that the GAP activity was associated with a protein of 
molecular mass in excess of 400 000 Da. This is similar to 
the results obtained for ral-GAP present in rat brain and 
mouse testis cytosolic fraction [18]. Attempts to dissociate 
the ral-GAP complex using high salt or urea were unsuc- 
cessful. Thus, to further characterize the cytosolic and 
particulate protein(s) responsible for stimulating the GT- 
Pase activity of ralA, platelet proteins from these fractions 
were separated using SDS-PAGE as described in Section 
2. The presence of GAP activity in gel slices was mea- 
sured by addition of proteins eluted from the gel to the 
GTPase assay. As shown in Fig. 6, ral-GAP activity in the 
cytosolic and particulate fractions was recovered in a 
single gel slice of identical apparent molecular weight. By 
comparing mobility of standard proteins on SDS-PAGE to 
that of the GTPase activating activity, the molecular mass 
of ral-GAP was determined to be 34 + 2 kDa (n = 5). An 
identical molecular mass for ral-GAP was obtained when 
platelets were lysed by the addition of Laemmli's sample 
buffer, the proteins separated using SDS-PAGE and GAP 
activity in gel pieces measured. This suggests that ral-GAP 
present in the cytosolic and particulate fraction was not 
proteolytically degraded. The specificity of ral-GAP was 
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Fig. 6. Determination of the molecular mass of platelet raI-GAP. To 1 
vol. of platelet cytosolic ( • )  or solubilized particulate (z~) proteins (150 
/xg), 4 vol. of Laemmli's sample buffer was added. After heating at 56°C 
for 3 min the proteins were separated by SDS-PAGE. The gel was 
equilibrated as described in Section 2. At the end of the equilibration 
period, the gel was cut into slices and the proteins eluted. An aliquot of 
the eluted proteins from each gel piece was used in the GTPase assay. 
GAP activity shown above represents the percentage decrease in the 
amount of radioactivity associated with ralA in the presence of GAP vs. 
that associated with ralA in the absence of addition of proteins eluted 
from the gel. 
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confirmed by the fact that t]his protein did not stimulate the 
intrinsic GTPase rate of ras p21, G25K/CDC42Hs or the 
rab3A proteins (results not shown). 
4. Discussion 
In order to investigate the regulation of GTPase activity 
of ral by the GTPase activating protein, we have ex- 
pressed the human ralA protein in E. coli and purified the 
recombinant protein to homogeneity. Although the purified 
fusion protein was proteolytically cleaved at the C- 
terminus, it was able to bind and hydrolyze GTP. The 
basal GTPase rate for ralA obtained in the current study is 
lower than that reported for this protein by Frech et al. 
[31]. The reason for this discrepancy is not clear. It could 
be due to differences in the assay conditions used in the 
two studies. However, using the ralA fusion protein pro- 
duced in the current study we have established the exis- 
tence of ral specific GAP in human platelets. Even though 
in platelets the ral-related GTP-binding protein(s) are 
firmly associated with the particulate fraction [24,25], GAP 
activity for ral was detected in approximately equal 
amounts in the cytosolic and particulate fraction. This type 
of subcellular distribution has been reported for GAP for 
rapl [15], rho [16], G25K/CDC42Hs [17] and rab3A 
[32]. The intrinsic GTPase ,activity of ralA was stimulated 
at least six-fold by ral-GAP. This degree of stimulation is 
of the same magnitude as that reported for GAPs for some 
of the other ras-related GTP-binding proteins. However, it 
is much lower than the 105-fold stimulation of the basal 
GTPase activity of ras p21 by ras-GAP [33]. 
When ral-GAP was analyzed by molecular exclusion 
chromatography, a molecular mass in excess of 400000 
Da was obtained. This is in agreement with the value 
obtained for raI-GAP from rat brain and mouse testis 
cytosol [18] suggesting that platelet raI-GAP may be 
similar to that present in other tissues. However, to date no 
protein of molecular mass in the range of 400 kDa has 
been implicated in the regulation of the GTPase activity of 
ras-related proteins suggesting that ral-GAP may exist in 
a complex with itself and/or  other protein(s) in the platelet. 
Thus, to further characteriz~e platelet raI-GAP, we deter- 
mined GAP activity in proteins eluted from gel slices after 
their separation by SDS-PAGE. The results demonstrated 
that the cytosolic and particulate ral-GAP activity was 
recovered in a gel slice of identical apparent molecular 
weight. The molecular ma,;s of ral-GAP was determined 
to be 34 + 2 kDa. This is clearly different from the ras 
p21 GAP which has a molecular mass of 125 kDa [9]. 
Furthermore, the raI-GAP detected in proteins eluted from 
the gel did not stimulate the intrinsic GTPase activity of 
ras p21. This is despite the fact that of all the newly 
identified ras p21 related GTP-binding proteins, the ral 
proteins share the greatest degree ( ~  50%) of homology 
with ras p21 [21]. 
GAPs have been purified from a variety of tissues and 
cell sources for some of the low molecular mass GTP-bi- 
nding proteins. Thus, rapl-GAP is a 85-95 kDa [14] and a 
55 kDa [15] protein, G25K/CDC42Hs-GAP is a 25 kDa 
protein [17], rho-GAP is a 27.5 to 28 kDa [16] protein and 
rab3A-GAP has molecular mass of 295 kDa [32]. The 
molecular mass of 34 kDa reported for ral-GAP in the 
present study is clearly different from the GAPs for rapl 
and rab3A proteins. In addition, we have reported in the 
present study that ral-GAP does not stimulate the intrinsic 
GTPase activity of the rab3A protein. The molecular mass 
of the G25K/CDC42Hs-GAP and rho-GAP are in the 
range of that for ral-GAP. However, ral-GAP did not 
stimulate the intrinsic GTPase  activity of the 
G25K/CDC42Hs protein. In addition, the gene for 
CDC42Hs-GAP has been recently cloned and sequenced 
and shown to code for a protein of 54 kDa and the earlier 
form of G25K/CDC42Hs-GAP is considered to be a 
proteolytic fragment [34]. Furthermore, it has been shown 
that G25K/CDC42Hs-GAP can stimulate the GTPase ac- 
tivity of rho [17]. Thus, it is likely that G25K/CDC42Hs 
belongs to the rho subfamily of GTP-binding proteins and 
it is unlikely that ral-GAP is identical to the 
G25K/CDC42Hs or rho GTPase activating proteins. 
Thus, the present study represents the initial report 
establishing molecular mass of the ral specific GTPase 
activating protein. Purification and partial/full sequencing 
of ral-GAP should help define, its homology to other 
known GAPs, its structural features and its role in the 
regulation of the function of ral-related proteins in platelet 
signalling pathways. 
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